866-997-4948(US-Canada Toll Free)

HER2 Antibodies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

Published By :

Transparency Market Research

Published Date : Aug 2017

Category :

Biotechnology

No. of Pages : 112 Pages

Global HER2 Antibodies Market: Overview

Among all the chronic diseases worldwide cancer is considered to be the most prevalent disease. Approximately 1,685,210 new cancer cases were diagnosed and about 595,690 cancer deaths in the US in year 2016. Whereas around 2,600 men and 246,660 that is about 29% women were diagnosed with breast cancer in year 2016. HER2 breast cancer is one of the aggressive type of breast cancer, caused due to over-expression of the HER2 protein. Breast cancers that overexpress the HER2 protein (known as HER2+) make up about 20% of the cases. HER2 positive breast cancer inclines to grow more rapidly than HER2 negative breast cancer. The factors such as being overweight, long term heavy smoking, use of menopausal hormone therapy, alcohol consumption, physical inactivity and many more are responsible for increasing risk of breast cancer. Increasing incidence of breast cancer is expected to lead to increase in demand for targeted therapies and boost the growth of the HER2 antibodies market during the forecast period.

Global HER2 Antibodies Market: Research Methodology

This report analyzes the current and future prospects of the HER2 antibodies market based on type of treatment drugs and geography. The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major HER2 antibody drugs in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for each type of treatment drug, and geography for the period 2016 to 2025, considering the macro and micro environmental factors. The revenue generated from each drug was calculated by considering number of drugs used in the treatment and their market demand and sales as per their use, number of new drug launched, trends in industry, awareness, and adoption rate across all the geographies. The prevalence of HER2 breast cancer was also considered while estimating the market revenue.

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on type of treatment drugs and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influence the HER2 antibodies market in the current and future scenario. The report also provides pipeline analysis of the upcoming drugs for HER2 breast cancer.

Global HER2 Antibodies Market: Competitive Landscape

Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the market. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for countries of North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the HER2 antibodies market report are Genentech Inc. (F. Hoffmann-La Roche Ltd.), Novartis AG, Pfizer, Inc., Abnova Corporation, InvivoGen, Celltrion, Inc., Biocon Limited, and Bio-Techne (Novus Biologicals, LLC) and some other players who are involved in the HER2 antibodies market.

The global HER2 Antibodies market is segmented as follows:

Global HER2 Antibodies Market Revenue, by Type of Treatment Drugs

  • Trastuzumab
  • Lapatinib 
  • Ado-trastuzumab emtansine 
  • Pertuzumab   
  • Everolimus  
     

Global HER2 Antibodies Market Revenue, by Geography

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global HER2 Antibodies Market

4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Key Market Indicators
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
4.4.4. Trends
4.5. Global HER2 Antibodies Market Analysis and Forecasts, 2015–2025
4.5.1. Market Revenue Projections (US$ Mn)
4.6. Porter’s Five Force Analysis
4.7. Market Outlook

5. Global HER2 Antibodies Market, Analysis and Forecasts, By Type of Treatment Drugs
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Market Value Forecast by Type of Treatment Drugs, 2015–2025
5.3.1. Trastuzumab
5.3.2. Lapatinib
5.3.3. Ado-trastuzumab emtansine
5.3.4. Pertuzumab
5.3.5. Everolimus

6. Global HER2 Antibodies Market Analysis and Forecasts, By Region
6.1. Key Findings
6.2. Market Value Forecast by Region
6.2.1. North America
6.2.2. Europe
6.2.3. Asia Pacific
6.2.4. Latin America
6.2.5. Middle East and Africa
6.3. Market Attractiveness by Country/Region

7. North America HER2 Antibodies Market, Analysis and Forecast
7.1. Introduction
7.1.1. Key Findings
7.1.2. Policies and Regulations
7.1.3. Key Trends
7.2. Market Value Forecast by Country, 2015–2025
7.2.1. U.S.
7.2.2. Canada
7.3. Market Attractiveness by Country
7.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
7.4.1. Trastuzumab
7.4.2. Lapatinib
7.4.3. Ado-trastuzumab emtansine
7.4.4. Pertuzumab
7.4.5. Everolimus
7.5. Market Attractiveness by Type of Treatment Drugs

8. Europe HER2 Antibodies Market, Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.1.2. Policies and Regulations
8.1.3. Key Trends
8.2. Market Value Forecast by Country, 2015–2025
8.2.1. U.K.
8.2.2. Germany
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Market Attractiveness by Country
8.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
8.4.1. Trastuzumab
8.4.2. Lapatinib
8.4.3. Ado-trastuzumab emtansine
8.4.4. Pertuzumab
8.4.5. Everolimus
8.5. Market Attractiveness by Type of Treatment Drugs

9. Asia Pacific HER2 Antibodies Market, Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Policies and Regulations
9.1.3. Key Trends
9.2. Market Value Forecast by Country, 2015–2025
9.2.1. Japan
9.2.2. China
9.2.3. India
9.2.4. Australia & New Zealand
9.2.5. Rest of Asia Pacific
9.3. Market Attractiveness by Country
9.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
9.4.1. Trastuzumab
9.4.2. Lapatinib
9.4.3. Ado-trastuzumab emtansine
9.4.4. Pertuzumab
9.4.5. Everolimus
9.5. Market Attractiveness by Type of Treatment Drugs

10. Latin America HER2 Antibodies Market, Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Policies and Regulations
10.1.3. Key Trends
10.2. Market Value Forecast by Country, 2015–2025
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of LATAM
10.3. Market Attractiveness by Country
10.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
10.4.1. Trastuzumab
10.4.2. Lapatinib
10.4.3. Ado-trastuzumab emtansine
10.4.4. Pertuzumab
10.4.5. Everolimus
10.5. Market Attractiveness by Type of Treatment Drugs

11. Middle East & Africa HER2 Antibodies Market, Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Policies and Regulations
11.1.3. Key Trends
11.2. Market Value Forecast by Country, 2015–2025
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. Rest of MEA
11.3. Market Attractiveness by Country
11.4. Market Value Forecast by Type of Treatment Drugs, 2015–2025
11.4.1. Trastuzumab
11.4.2. Lapatinib
11.4.3. Ado-trastuzumab emtansine
11.4.4. Pertuzumab
11.4.5. Everolimus
11.5. Market Attractiveness by Type of Treatment Drugs

12. Pipeline Analysis
12.1. Pipeline Snapshot for HER2 Antibodies Market

13. Competition Landscape
13.1. Heat Map Analysis by Company (2016)
13.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
13.2.1. Novartis AG
13.2.1.1. Company Overview
13.2.1.2. Business Overview
13.2.1.3. Financial Overview
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.2. Pfizer, Inc.
13.2.1.1. Company Overview
13.2.1.2. Business Overview
13.2.1.3. Financial Overview
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.3. Genentech Inc. (F. Hoffmann-La Roche Ltd.)
13.2.1.1. Company Overview
13.2.1.2. Business Overview
13.2.1.3. Financial Overview
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.4. Abnova Corporation
13.2.1.1. Company Overview
13.2.1.2. Business Overview
13.2.1.3. Financial Overview
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.5. InvivoGen
13.2.1.1. Company Overview
13.2.1.2. Business Overview
13.2.1.3. Financial Overview
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.6. Celltrion, Inc.
13.2.1.1. Company Overview
13.2.1.2. Business Overview
13.2.1.3. Financial Overview
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.7. Biocon Limited
13.2.1.1. Company Overview
13.2.1.2. Business Overview
13.2.1.3. Financial Overview
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.8. Bio-Techne (Novus Biologicals, LLC)
13.2.1.1. Company Overview
13.2.1.2. Business Overview
13.2.1.3. Financial Overview
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview

List of Table

Table 01: Global HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 02: Global HER2 Antibodies Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 03: North America HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 04: North America HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 05: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 06: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 07: Asia Pacific HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 08: Asia Pacific HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 09: Latin America HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 10: Latin America HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025
Table 11: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 12: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) Forecast, by Type of Treatment Drugs, 2015–2025

List of Chart

Figure 01: HER2 Antibodies Market, by Type of Treatment Drugs, Market Size (US$ Mn), 2016 (A)
Figure 02: HER2 antibodies market revenue (%), by top three drugs, 2016 (A)
Figure 03: Executive Summary (2/3)
Figure 04: Executive Summary (3/3)
Figure 05: Opportunity Map, 2017
Figure 06: Key Industry Developments
Figure 07: Drivers and Restraints Snapshot (1/1)
Figure 08: Global HER2 Antibodies Market Size (US$ Mn) Forecast, 2015–2025
Figure 09: Porter’s Five Forces Analysis (1/2)
Figure 10: Global HER2 Antibodies Market Value Share, by Type of Treatment Drugs (2016)
Figure 11: Global HER2 Antibodies Market Value Share, by Region (2016)
Figure 12: Global HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 13: Global HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 14: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Trastuzumab, 2015–2025
Figure 15: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Lapatinib, 2015–2025
Figure 16: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Ado-trastuzumab Emtansine, 2015–2025
Figure 17: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Pertuzumab, 2015–2025
Figure 18: Global HER2 Antibodies Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Everolimus, 2015–2025
Figure 19: Global Market Scenario
Figure 20: Global HER2 Antibodies Market Value Share, by Region, 2017 and 2025 
Figure 21: Global HER2 Antibodies Market Attractiveness, by Region, 2017–2025
Figure 22: North America HER2 Antibodies Market Size (US$ Mn) Forecast, and Y-o-Y Growth (%) Forecast, by region, 2015–2025
Figure 23: North America HER2 Antibodies Market Attractiveness Analysis, by Country
Figure 24: North America HER2 Antibodies Market Value Share Analysis, by Country, 2017 and 2025
Figure 25: North America HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 26: North America HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 27: Europe HER2 Antibodies Market Size (US$ Mn) Forecast, and Y-o-Y Growth (%) Forecast, by region, 2015–2025
Figure 28: Europe HER2 Antibodies Market Attractiveness Analysis, by Country, 2017-2025
Figure 29: Europe Market Value Share Analysis, by Country, 2017 and 2025
Figure 30: Europe HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 31: Europe HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 32: Asia Pacific HER2 Antibodies Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
Figure 33: Asia Pacific HER2 Antibodies Market Attractiveness Analysis, by Country. 2017-2025
Figure 34: Asia Pacific Market Value Share Analysis, by Country, 2017 and 2025
Figure 35: Asia Pacific HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 36: Asia Pacific HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 37: Latin America HER2 Antibodies Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2015–2025
Figure 38: Latin America HER2 Antibodies Market Attractiveness Analysis, by Country, 2017-2025
Figure 39: Latin America Market Value Share Analysis, by Country, 2017 and 2025
Figure 40: Latin America HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 41: Latin America HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 42: Middle East & Africa HER2 Antibodies Market Size (US$ Mn) and
Figure 43: Middle East & Africa HER2 Antibodies Market Attractiveness Analysis, by Country, 2017-2025
Figure 44: Middle East & Africa Market Value Share Analysis, by Country, 2017 and 2025
Figure 45: Middle East & Africa HER2 Antibodies Market Value Share, by Type of Treatment Drugs, 2017 and 2025
Figure 46: Middle East & Africa HER2 Antibodies Market Attractiveness, by Type of Treatment Drugs, 2017–2025
Figure 47: Pipeline Snapshot of HER2 Antibodies Market (1/2)
Figure 48: Pipeline Snapshot of HER2 Antibodies Market (2/2)
Figure 49: Global HER2 Antibodies Market Heat Map Analysis by Company (2016)
Figure 50: Novartis AG Breakdown of Net Sales, by Region (2016)
Figure 51: Novartis AG Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 52: Pfizer, Inc. Breakdown of Net Sales, by Region (2016)
Figure 53: Pfizer, Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 54: Genentech Inc. Breakdown of Net Sales, by Segment, 2016
Figure 55: Genentech Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 56: Abnova Corporation Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 57: Celltrion, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2015
Figure 58: Biocon Limited Breakdown of Net Sales, by Business Segments, 2016
Figure 59: Biocon Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 60: Bio-Techne Breakdown of Net Sales, by Business Segment, 2016
Figure 61: Bio-Techne Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *